Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K.
McCourt CK, Wei Z, Kalinsky K, Gray R, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Force J, Pakanati A, Tricoli JV, Conley BA, Arteaga C, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. McCourt CK, et al. Among authors: patton dr. Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-24-3431. Online ahead of print. Clin Cancer Res. 2025. PMID: 40577532
A Concordance Study Among 26 NGS Laboratories Participating in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Clinical Trial.
Zane LK, Yee LM, Chang TC, Sklar J, Yang G, Wen JD, Li P, Harrington R, Sims DJ, Harper K, Trent JM, LoBello JR, Szelinger S, Benson K, Zeng J, Poorman K, Xu D, Frampton GM, Pavlick DC, Miller VA, Tandon B, Swat W, Weiss L, Funari VA, Conroy JM, Prescott JL, Chandra PK, Ma C, Champion KJ, Baschkopf GX, Fesko YA, Freitas TAK, Tomlins SA, Hovelson DH, White K, Sorrells S, Tell R, Beaubier N, King D, Li L, Kelly K, Uvalic J, Meyers B, Kolhe R, Lindeman NI, Baltay M, Sholl LM, Lopategui J, Vail E, Zhang W, Telatar M, Afkhami M, Hsiao SJ, Mansukhani MM, Adams E, Jiang L, Aldape KD, Raffeld M, Xi L, Stehr H, Segal JP, Aisner DL, Davies KD, Brown NA, Livingston RJ, Konnick EQ, Song W, Solomon JP, Walther Z, McShane LM, Harris LN, Chen AP, Tsongalis GJ, Hamilton SR, Flaherty KT, O'Dwyer PJ, Conley BA, Patton DR, Iafrate AJ, Williams PM, Tricoli JV, Karlovich C. Zane LK, et al. Among authors: patton dr. Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-2188. Online ahead of print. Clin Cancer Res. 2025. PMID: 40465838
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Gouda MA, Wei Z, Rodon J, Davies MA, Janku F, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Liu R, Bota DA, Swiecicki PL, Buchschacher GL, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gouda MA, et al. Among authors: patton dr. JCO Precis Oncol. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6. JCO Precis Oncol. 2025. PMID: 39913886 Clinical Trial.
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Zauderer MG, Jegede O, Jackman DM, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Huang R, Carrillo JA, Brenner AJ, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Zauderer MG, et al. Among authors: patton dr. JCO Precis Oncol. 2024 Dec;8:e2400327. doi: 10.1200/PO.24.00327. Epub 2024 Dec 18. JCO Precis Oncol. 2024. PMID: 39693587 Clinical Trial.
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.
Schoenfeld JD, Azad NS, Gross J, Chen L, Overman MJ, Kao K, Jackson L, Brunnquell D, Bu X, Coppola C, Guan P, Lee J, Sims D, Fuchs R, Weirather JL, Pfaff KL, Gunasti L, Ranasinghe S, Hamilton SR, Wang V, O'Dwyer PJ, Wu CJ, Rodig SJ, Patton DR, Harris L. Schoenfeld JD, et al. Among authors: patton dr. Clin Cancer Res. 2025 Feb 17;31(4):667-677. doi: 10.1158/1078-0432.CCR-24-0427. Clin Cancer Res. 2025. PMID: 39670863 Free PMC article.
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
Gien LT, Song Z, Poklepovic A, Collisson EA, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gien LT, et al. Among authors: patton dr. JCO Precis Oncol. 2024 Dec;8:e2400514. doi: 10.1200/PO-24-00514. Epub 2024 Dec 12. JCO Precis Oncol. 2024. PMID: 39666929 Clinical Trial.
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
O'Hara MH, Jegede O, Dickson MA, DeMichele AM, Piekarz R, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Onitilo A, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. O'Hara MH, et al. Among authors: patton dr. Clin Cancer Res. 2025 Jan 6;31(1):56-64. doi: 10.1158/1078-0432.CCR-24-0036. Clin Cancer Res. 2025. PMID: 39437014 Clinical Trial.
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).
Macy ME, Mody R, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Williams PM, Patton DR, Coffey BD, Roy-Chowdhuri S, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Macy ME, et al. Among authors: patton dr. JCO Precis Oncol. 2024 Sep;8:e2400418. doi: 10.1200/PO-24-00418. JCO Precis Oncol. 2024. PMID: 39298716 Clinical Trial.
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D.
Laetsch TW, Ludwig K, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Mhlanga J, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Laetsch TW, et al. Among authors: patton dr. JCO Precis Oncol. 2024 Sep;8:e2400258. doi: 10.1200/PO.24.00258. JCO Precis Oncol. 2024. PMID: 39298693 Clinical Trial.
Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.
Gettinger SN, Song Z, Reckamp KL, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Kong XT, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gettinger SN, et al. Among authors: patton dr. JCO Precis Oncol. 2024 Jul;8:e2300725. doi: 10.1200/PO.23.00725. JCO Precis Oncol. 2024. PMID: 38986051 Clinical Trial.
41 results